Latest California Healthline Stories
Change to Gilead Assistance Program Threatens PrEP Access, HIV Advocates Say
Safety-net clinics especially are bracing for how the drugmaker’s policy shift could reduce their budgets and hamstring their ability to provide care to an at-risk population.
FDA Weighs Approval of a Lucrative Alzheimer’s Drug, but Benefits Are Iffy
The agency is to decide by June 7 whether to greenlight Biogen’s drug aducanumab, despite a near-unanimous rejection of the product by an FDA advisory committee of outside experts in November. Some scientists at the agency have endorsed the drug, though.
KHN’s ‘What the Health?’: The Drug Price Dilemma
Republicans, Democrats and the public at large agree that prices for prescription drugs are too high. But no one seems to know how to fix it. Vanderbilt University drug price researcher Stacie Dusetzina explains the basics of why drugs cost so much and why it’s hard to do something about it. Joanne Kenen of Politico, Sarah Karlin-Smith of the Pink Sheet and Anna Edney of Bloomberg News join KHN’s Julie Rovner to discuss the prospects for policy changes.
Biden Administration Signals It’s in No Rush to Allow Canadian Drug Imports
Federal officials asked a court to dismiss a suit by drugmakers over the policy enacted by the Trump administration that would allow states to bring in cheaper prescription medications from Canada. The filing said the lawsuit was moot because it’s unclear when or if the FDA would approve any state’s importation plan.
Opioids like ‘Lean’ Permeate Hip-Hop Culture, but Dangers Are Downplayed
In big cities and small towns, opioid use among some young hip-hop fans is about emulating their favorite rap star’s image — while paying little attention to the serious consequences.
KHN’s ‘What the Health?’: The Return of the Public Option
Lawmakers are working on fleshing out the concept of a “public option,” a government-run or heavily regulated insurance plan that would compete with private insurance. But the details are complicated, both substantively and politically. Meanwhile, bioethicists are debating whether the U.S. should be vaccinating low-risk adolescents against covid-19 while high-risk adults in other countries are still waiting. Margot Sanger-Katz of The New York Times, Alice Miranda Ollstein of Politico and Rachana Pradhan of KHN join KHN’s Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
Colorado Lawmakers Wage Multifront Assault on High Drug Costs
Colorado is one of many states resolved not to wait for federal action to reduce drug costs. Its legislature is considering several ways to lower costs for consumers and the state.
Legisladores de Colorado se posicionan contra los altos costos de los medicamentos
Incapaz de fijar los precios o cambiar las protecciones de las patentes, el estado considera medidas legislativas y administrativas para reducir los gastos de bolsillo delos consumidores.
KHN Journalists Comment on Abortion Case, Wasted Covid Doses
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
KHN’s ‘What the Health?’: Drug Price Effort Hits a Snag
Democratic leaders in Congress have vowed to pass legislation to address high prescription drug prices this year, but some moderates in their own party appear to be balking. Meanwhile, younger teens are now eligible for a covid-19 vaccine and the Biden administration reinstated anti-discrimination policy for LGBTQ people in health care. Joanne Kenen of Politico, Sarah Karlin-Smith of the Pink Sheet and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more.